Do you want to read an article? Please log in or register.
Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis
Inflammatory Bowel Disease
Related content
RECOMMENDED
Inflammatory Bowel Disease
Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S
doi: 10.1093/ecco-jcc/jjaa027.
Inflammatory Bowel Disease
Validation of the "German Inflammatory Bowel Disease Activity Index (GIBDI)": An Instrument for Patient-Based Disease Activity Assessment in Crohn's Disease and Ulcerative Colitis
Z Gastroenterol.
Hüppe A, Langbrandtner J, Häuser W, Raspe H, Bokemeyer B
doi: 10.1055/a-0605-4080.
Inflammatory Bowel Disease
Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort
J Crohns Colitis.
Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Jenkinson PW, Lam WL, Lyons M, Macdonald JC, MacMaster M, Mowat C, Naismith GD, Potts LF, Saffouri E, Seenan JP, Sengupta A, Shasi P, Sutherland DI, Todd JA, Veryan J, Watson AJM, Watts DA, Jones GR, Lees CW
doi: 10.1093/ecco-jcc/jjz042.
Inflammatory Bowel Disease
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review
BMC Gastroenterol.
Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R
doi: 10.1186/s12876-020-01332-w.
Inflammatory Bowel Disease
Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis
Inflamm Bowel Dis.
Nguyen NH, Kurnool S, Dulai PS, Boland BS, Sandborn WJ, Singh S
doi: 10.1093/ibd/izz276.
Inflammatory Bowel Disease
Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study
J Crohns Colitis.
Burisch J, Katsanos KH, Christodoulou DK, Barros L, Magro F, Pedersen N, Kjeldsen J, Vegh Z, Lakatos PL, Eriksson C, Halfvarson J, Fumery M, Gower-Rousseau C, Brinar M, Cukovic-Cavka S, Nikulina I, Belousova E, Myers S, Sebastian S, Kiudelis G, Kupcinskas L, Schwartz D, Odes S, Kaimakliotis IP, Valpiani D, D'Incà R, Salupere R, Zammit SC, Ellul P, Duricova D, Bortlik M, Goldis A, Kievit HAL, Toca A, Turcan S, Midjord J, Nielsen KR, Andersen KW, Andersen V, Misra R, Arebi N, Oksanen P, Collin P, de Castro L, Hernandez V, Langholz E, Munkholm P1, Epi-IBD Group
doi: 10.1093/ecco-jcc/jjy154.
RECOMMENDED
Inflammatory Bowel Disease
DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in Ulcerative Colitis
J Crohns Colitis.
Rowan CR, Cullen G, Mulcahy HE, Sheridan J, Moss AC, Ryan EJ,
Doherty GA
doi: 10.1093/ecco-jcc/jjz067.
COMMENTED
Inflammatory Bowel Disease
Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis
Inflamm Bowel Dis.
Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS
doi: 10.1093/ibd/izy307.
Inflammatory Bowel Disease
Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease but Not Ulcerative Colitis
Clin Gastroenterol Hepatol.
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland B, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R
doi: 10.1016/j.cgh.2018.12.040.